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Glycemic control in patients with diabetes mellitus type 1 (DM1) reduces the risk of complications 
but requires a rigorous health care routine. Thus, diabetes education is central to increasing treatment 
compliance and self-care practices. This study aimed to evaluate the quality of life (QoL) and glycemic 
control of DM1 patients being treated with insulin analogs and receiving medication review with follow-
up. This was a transversal study that included 110 patients registered at the 3rd Health Regional of Ponta 
Grossa-PR, aged ≥ 18 years, and receiving pharmaceutical care for at least 1 year. The Diabetes Quality 
of Life Measure (DQOL)-Brazil was used to evaluate QoL. The data were statistically analyzed using 
SPSS version 17.0 with 95% confidence levels. Of the 110 patients, 58.2% were women. The average 
age was 33.7 years (±10.5), and the average glycated hemoglobin (HbA1c) value was 8% (±1.4). The 
mean total DQOL-Brazil score was 2.11 (95% confidence interval, 2.02 – 2.21). All DQOL-Brazil scores 
were lower in patients with HbA1c ≤ 8%, indicating a better QoL. Good glycemic control, thus, appears 
to have a positive influence on the QoL, and pharmaceutical interventions are able to contribute to the 
achievement of therapeutic targets.
Uniterms: Diabetes mellitus type 1/treatment. Diabetes mellitus type 1/treatment/quality of life. 
Pharmaceutical care. Insulin analogs. Pharmacotherapy follow-up. 
INTRODUCTION
Diabetes mellitus (DM) is a group of metabolic 
d i sorders  p r imar i ly  charac te r ized  by  chron ic 
hyperglycemia. High glycemic levels are associated 
with micro- and macrovascular complications leading 
to damage to, and failure of organs such as the eyes 
(retinopathy), kidneys (nephropathy), nerves (neuropathy), 
heart, and blood vessels (ADA, 2016; Braga de Souza et 
al., 2015; Gross et al., 2002). 
According to the Diabetes Control and Complications 
Trial (DCCT), the risk of developing chronic complications 
is higher in patients with chronically high glycated 
hemoglobin (HbA1c) levels, and the risk gradually 
increases with HbA1c levels greater than 7% (Pimazoni 
Netto et al., 2009). The American Diabetes Association 
(ADA) defines an HbA1c value < 7% as the acceptable 
limit for diabetes control. With good glycemic control, 
patients can be symptom-free, and prevent acute and 
chronic complications (ADA, 2016; UKPDS, 1999; 
DCCT, 1988). 
DM is a chronic condition that requires daily 
self-care throughout life and has a negative impact on 
the subjective perception of the quality of life (QoL). 
However, daily treatment is fundamental to DM control 
and decreases the risk of complications (Debaty et al., 
2008; Wood-Dauphinee, 1999). DM1 therapy includes 
intensive care demands such as daily blood glucose 
monitoring, multiple insulin injections, and specific 
dietary and physical activity recommendations (ADA, 
2016). Not understanding all these recommendations and 
a lack of compliance to treatment leads to a poor glycemic 
control that can cause severe hyper- or hypoglycemia 
episodes and chronic complications, affecting QoL. 
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Furthermore, a constant fear of these acute and chronic 
complications can also decrease QoL perception (Braga 
de Souza et al., 2015; Trento et al., 2013). 
Understanding every stage of insulin treatment 
and non-pharmacological therapy besides the risk 
of developing complications is essential to achieve 
therapeutic targets. However, some patients have social, 
cultural, and educational limitations that may decrease 
compliance to treatment (Kahlili et al., 2016; Braga de 
Souza, et al., 2015; Jimmy, Jose, 2011). Thus, diabetes 
education and continued patient follow-up are central 
to increasing knowledge of the disease and treatment, 
developing self-care skills, and reducing and maintaining 
glycemic levels as established by the ADA, all of which 
have a positive effect on QoL perception (Brasil, 2013; 
Falconier et al., 2009; Debaty et al., 2008). 
In this context, diabetic patients’ QoL is influenced 
by factors such as age, sex, obesity, comorbidities, 
complications, knowledge regarding DM, type of 
treatment, and glycemic control. The Health-Related 
Quality of Life (HRQoL) has been used to evaluate the 
impact of diabetes and its treatment on patient humanistic 
outcomes as it relates health, not to the absence of disease, 
but as complete physical; mental; and social well-being 
(Braga de Souza et al., 2015; Trento et al., 2013; Falconier 
et al., 2009; Debaty et al., 2008; Cases et al., 2003; 
HSGCD, 2001; Testa, Simonson, 1996).
The Diabetes Quality of Life Measure (DQOL), 
which measures the disease impact and the restrictions 
imposed on different areas of daily life, is the most 
commonly used instrument to evaluate QoL in patients 
with diabetes (Brasil et al., 2015; Brasil, 2013; Falconier et 
al., 2009; Debaty et al., 2008; Cases et al., 2003; Redekop 
et al., 2002; HSGCD, 2001; Testa, Simonson, 1996; 
Gafni, Birch, 1993). It was originally developed by the 
DCCT group in English, and the Portuguese version was 
translated, adapted, and validated in Brazil (Brasil et al., 
2015; Correr et al., 2008; Melchiors et al., 2005; Coffey, 
Brandle, Zhou, 2002; DCCT, 1988).
QoL has been used around the world as a relevant 
parameter to evaluate the results and quality of health 
care services; it is particularly useful for patients with 
chronic diseases in whom the QoL is a critical outcome 
once the cure of chronic condition is not ensured (Quah et 
al., 2016; Haines et al., 2016; Trento et al., 2013; Wood-
Dauphinee, 1999). Studies suggest that the type of insulin 
treatment can modify QoL perception. Insulin analogs 
demonstrate better glycemic control with less severe 
episodes of hypoglycemia and postprandial hyperglycemia 
when compared with human insulin, and produce greater 
satisfaction with treatment, and thus, can have a positive 
impact on the QoL of DM patients (Wojciechowski et al., 
2015; Rys et al., 2011; Shatlin, Philip, 2008). Therefore, 
this study evaluated the QoL of DM1 patients being treated 
with insulin analogs and receiving medication reviews 
with follow-up.
MATERIAL AND METHODS
Participants
Patients were invited to participate in the study 
at the time of drug dispensation. The sample size was 
calculated based on a 5% rate of error and a 95% level 
of confidence. The sampling process was systematic, 
based on accessibility sampling (Marotti et al., 2008), 
and in accordance with the  inclusion and exclusion 
criteria. The inclusion criteria for participation were: age 
≥ 18 years, a diagnosis of DM1, treatment with insulin 
analogs and medication review with follow-up for at 
least a year, and indication of willingness to participate 
in this research by signing the Terms of Consent (TCLE). 
Patients with high understanding- and visual difficulties, 
hypoglycemia or mental confusion at the time of 
questionnaire administration, and those that did not fit the 
inclusion criteria were excluded. 
This is a transversal study, performed at the 
Especial Pharmacy of 3rd Health Regional of Ponta 
Grossa-PR, where patients are registered to receive free 
DM1 medication and supplies and are included in the 
pharmaceutical care program. Medications are dispensed 
monthly; the patient’s health condition is evaluated at 
the first dispensation, and pharmaceutical care service is 
offered. Glycemic control is assessed based on HbA1c 
values, and frequency of hypo- or hyperglycemic 
events. Poor glycemic control, low understanding, and 
low treatment compliance result in increased frequency 
of pharmacist consultations. Medication review with 
follow-up is offered once a week in the first month, then 
once every two weeks, and then once a month until the 
participating patients fully understand the treatment with 
insulin analogs and non-pharmacological treatment. 
The pharmaceutical  care service provided 
information and interventions such as a) insulin 
analogs therapy: handling automatic insulin delivery 
pens, injection techniques, frequency and schedule 
of administration, correct dose calculation of short-
acting insulin at every meal, risks of wrong dosage, 
transportation and home storage, and appropriate discard 
procedure for contaminated needles and lancets; b) 
blood glucose self-monitoring: technique, importance 
of daily monitoring, interpretation of glycemic results, 
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dealing with hypoglycemic episodes, need to achieve 
and maintaining HbA1c target, and education regarding 
the risk of acute and chronic complications; c) non-
pharmacological treatment: dietary and physical activity 
recommendations (patients are referred to a nutritionist or 
a physical educator, as needed). 
Sociodemographic data were obtained from 
questionnaire-based interviews. To evaluate glycemic 
control, we considered the most recent HbA1c values at 
the time of questionnaire administration. Questionnaire 
administration and data collection were conducted 
from July 2013 to December 2013. HbA1c values were 
collected from the electronic system of the Management 
and Follow-up of Medication unit of the Specialized 
Component of Pharmaceutical Assistance, where the 
patients are registered in the DM1 Optimization Program 
of the State of Parana to receive free DM1 treatment. 
HbA1c is one of the required parameters from the 
DM1 Optimization Program to evaluate glycemic control, 
and some studies have shown its negative influence on the 
QoL of patient with DM (Tahirovic et al., 2012; Campbell, 
2002; HSGCD, 2001). However, the impact of glycemic 
control on QoL remains controversial, and other variables 
need to be considered for more reliable results (Braga de 
Souza et al., 2015). Although validated instruments are 
available to evaluate treatment compliance (Jimmy, Jose, 
2011), in the context of the present study, HbA1c values 
were more appropriate as the focus was to evaluate QoL. 
Quality of life
QoL was evaluated using the DQOL-Brazil 
instrument consisting of 44 multiple-choice questions, 
divided into four domains: satisfaction (15 questions), 
impact (18 questions), vocational/social preoccupations 
(7 questions), and diabetes-related concerns (4 questions). 
The DQOL-Brazil answers are organized using an inverted 
5-point Likert scale, and scores range from 1 to 5. Scores 
closer to one reflect a better QoL.
The DQOL-Braz i l  i s  a  se l f -adminis te red 
questionnaire, but for patients with visual or motor skill 
impairments, the instrument was administered via a 
structured interview; the questions were read out exactly 
as written, and the answers were marked appropriately. To 
reduce bias the researchers administering the questionnaire 
received standard training to ask questions directly and 
without extra comments. 
Statistical analysis
To evaluate the internal consistency and questionnaire 
reliability, Cronbach’s alpha was calculated separately for 
each individual domain, and for the instrument as a whole. 
Values greater than 0.7 were considered acceptable (Hair 
et al., 1998).
The results were tested for normality of distribution 
using the Kolmogorov-Smirnov test, and other appropriate 
statistical tests were utilized.
Spearman’s correlation coefficient was used to 
identify associations between the DQOL-Brazil scores 
and the continuous variables in the sample population. 
The Mann-Whitney test was used to compare the averages.
Statistical calculations were performed using SPSS 
version 17.0 with a 95% confidence levels.
Ethics
This research project was approved by the Research 
Ethic Committee of State University of Ponta Grossa 
(protocol nº 127.211/2012). 
RESULTS
The calculated sample size was 130 patients. 
However, only 110 patients agreed to participate in the 
study and signed the TCLE. Of the 110 participants who 
answered the DQOL-Brazil questionnaire, 58.2% were 
women. The participants’ ages ranged from 19 to 65 years, 
with an average of 33.7 years (± 10.5). The average HbA1c 
value was 8.0% (±1.4), with a range of 5.0 to 12.1%. The 
mean duration of questionnaire administration was 10 
minutes. 
The average DQOL-Brazil score was 2.11 (95% 
confidence interval (CI) 2.02 – 2.21). Among the domains, 
the average scores were 2.17 (95% CI 2.04 – 2.29) for 
satisfaction, 2.08 (95% CI 1.99 – 2.18) for impact, 1.94 
(95% CI 1.77 – 2.10) for vocational/social preoccupations, 
and 2.37 (95% CI 2.23 – 2.50) for diabetes concern. 
The total score and the scores for satisfaction, 
impact, and diabetes concern exhibited a normal 
distribution on a Kolmogorov-Smirnov test; the age and 
HbA1c values were also normally distributed. However, 
normal distribution was not verified for vocational/social 
preoccupation domain score.
The reliability analyses (internal consistency) for the 
total questionnaire and its individual domains are shown 
in Table I.
The correlations between the individual domain 
scores and the total instrument score are presented in 
Table II. The DQOL-Brazil domains were interrelated 
and had significant positive correlations with the total 
questionnaire score (p < 0.01).
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We observed sex-specific differences in the 
perception of QoL (Table III). Women showed significantly 
higher scores in satisfaction, impact, diabetes concern 
domains, and in the total score than men. The vocational/
social preoccupation scores were not significantly 
different, even though they were higher in women.
Age was negatively correlated (p < 0.01) with the 
vocational/social preoccupations domain score suggesting 
that lower QoL scores and hence, a better perception of 
QoL was related to more advanced age.
HbA1c, which is a highly specific marker for DM, 
showed a significant positive correlation (p<0.05) with 
the scores for satisfaction and impact domains, as well as 
with the total instrument score.
Using glycemic control results as indicated by the 
HbA1c levels, the total and individual domain scores 
were compared to determine whether the questionnaire 
could distinguish participants with different HbA1c levels. 
The HbA1c level was chosen as it is the gold standard 
for diabetes treatment monitoring and as there is a direct 
relationship between a patient’s mean glycemia and the 
chronic disease complications (SBD, 2003).
As illustrated in Table IV, the average score for 
the total instrument, and for the satisfaction and impact 
domains differed based on participants’ HbA1c levels 
(>8% vs. <8%). Despite the lack of significance for the 
preoccupations domain, participants with HbA1c values ≤ 
8% exhibited lower scores for all the domains, indicating 
a better QoL. Therefore, our data suggests that better 
glycemic control is associated with a better subjective 
perception of QoL. 
DISCUSSION
The DQOL-Brazil questionnaire is divided into four 
domains that evaluate the influence of DM1 on several 
aspects of life: the impact of DM1 and its treatment on 
the social life, family, and job, and the impact the disease 
has on patient’s health-related concerns. Poor glycemic 
control greatly increases the likelihood of experiencing 
hypo- or hyperglycemic events, thereby increasing the 
risk of developing chronic complications, that can, in turn, 
affect the QoL perception of patients. 
Several studies have reported sex-specific differences 
in the QoL perception, and women usually score higher; 
TABLE I - Internal Consistency analysis of the Satisfaction, 
Impact, and Preoccupations domains of the DQOL-Brazil for 
DM1 patients
Number of items Cronbach’s alpha
Total DQOL-Brazil 44 0.92
Satisfaction 15 0.88
Impact 18 0.85
Vocational/Social 
preoccupations 
7 0.82
Diabetes concern 4 0.78
TABLE II - Correlations between the domain scores and the total score obtained from the DQOL-Brazil administered to DM1 patients
Satisfaction Impact Vocational/Social Preoccupations Diabetes Concern Total DQOL-Brazil
Satisfaction - 0.62 0.28 0.45 0.83
Impact 0.62 - 0.47 0.63 0.89
Vocational/Social 
Preoccupations
0.28 0.47 - 0.44 0.61
Diabetes Concern 0.45 0.63 0.44 - 0.70
Correlation analyses using Spearman’s coefficient. All the “r” values were significant (p<0.01).
TABLE III - Scores of DQOL-Brazil according to sex
Men Women p value
Satisfaction 1,99 2,29 0.013
Impact 1,98 2,16 0.033
Vocational/Social Preoccupation 1,85 2,00 0.229
Diabetes Concern 2,25 2,45 0.040
Total DQOL-Brazil 1,99 2,21 0.009
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indicating poorer QoL perception, when compared to men 
(Trento et al., 2013; Urzúa, Chirino, Valadares, 2011; 
HSGCD, 2001). Our results are in agreement with these 
reports. Women demonstrated worse QoL perception than 
men, and the differences were significant. Our results may 
be a reflection of the greater care towards health shown by 
women socially. Women seek health care services more 
frequently than men, and appear more vulnerable to the 
pressures imposed by DM1; the disease generates higher 
social concerns and worries in them, thus negatively 
affecting their QoL (Urzúa, Chirino, Valadares, 2011).
The age of the participants completing the 
questionnaire ranged from 19 to 65 years, imparting 
different perspectives in the “Vocational/Social 
Preoccupations” domain. This domain evaluates areas 
related to studies; jobs; and marriage, which, depending 
on the participant age, may not be a concern if they 
have already been achieved/overcome. Consequently, 
the younger the patient, the higher the vocational/social 
preoccupations score, indicating greater worries that result 
in a poor QoL perception. Older participants exhibit more 
adaptations within, and acceptance of the areas within this 
domain, thereby leading to lower scores and better QoL 
perceptions.
HbA1c test is currently considered the gold standard 
to verify metabolic control in DM1 patients, and although 
many studies have evaluated the influence of psychosocial 
factors beyond clinical factors on the QoL scores of 
patients with DM1 (Walker, Bradley, 2002; Trieff et al., 
2001), metabolic control plays a significant role in the 
subjective perception of QoL (Campbell, 2002; HSGCD, 
2001). Patients with HbA1c ≤ 8% had lower scores in all 
the DQOL-Brazil domains compared with patients with 
higher HbA1c values, suggesting that metabolic control 
affects the QoL and reduces the risk of acute and chronic 
complications, thereby also improving the perceived QoL.
A study performed in Bosnia and Herzegovina 
in 2012 evaluated the relationship between glycemic 
control and QoL in children and teenagers with DM1 
and demonstrated that children and teenagers with better 
metabolic control (HbA1c values <8%) had a better QoL 
than those with poor metabolic control (> 8%) (Tahirovic 
et al., 2012). Similarly, Vanelli et al. (2003) studied 
teenagers with DM1 in Italy and found that teenage 
patients with lower HbA1c values had fewer worries and 
a better overall QoL; teenagers with higher HbA1c values 
exhibited more discontent, a worse perception of their 
health condition, and the worst QoL scores. Both studies 
corroborate our results demonstrating a better perception 
of QoL in patients with HbA1c values ≤8%.
Maintaining HbA1c values within the target limits 
established by the ADA (ADA, 2016) requires an intense 
care routine. Compliance with a rigorous scheme of insulin 
treatments, as well as non-pharmacological treatments, 
requires effort and persistence by the patient, which itself 
can cause discomfort and may discourage the patients 
from comply the treatment, worsening QoL perception 
(Braga de Souza, et al., 2015). However, patients with 
lower HbA1c values had a better perception of their QoL 
indicating that intensive treatment, when it is understood 
and adopted as part of a routine, can prevent acute 
complications and positively influence QoL scores.
Part ic ipants  with  high HbA1c values  had 
significantly higher DQOL-Brazil scores, suggesting a 
worse perception of QoL. Poor glycemic control results 
in clinical conditions of hypo- or hyper-glycemia, which 
require frequent hospitalizations, thus increasing the 
impact of diabetes on the patient’s life, thereby reducing 
general life satisfaction and decreasing the subjective 
perception of QoL.
Saleh et al. (2014) evaluated DM2 patients from 
Bangladesh and demonstrated a similar relationship 
between treatment and QoL. Patients who were considered 
non-adherent to the treatment (diet, physical activity, 
smoking cessation, and glycemic values) had a lower QoL 
index (Saleh et al., 2014). However, the study by Martínez 
et al. (2008) on DM2 patients from México reported no 
association between QoL and treatment compliance but 
observed that the patients’ education levels influenced 
most QoL domains. Patients with higher education 
TABLE IV - DQOL-Brazil results for patients with DM1 stratified by HbA1c values greater or less than 8%
HbA1c ≤8% 
(N = 61)
HbA1c >8% 
(N = 49) p value
Total DQOL-Brazil 1.99 (1.87 – 2.11) 2.23 (2.11 – 2.36) 0.002
Satisfaction 1.96 (1.82 – 2.11) 2.38 (2.21 – 2.55) 0.001
Impact 2.00 (1.88 – 2.13) 2.15 (2.02 – 2.28) 0.044
Vocational/Social Preoccupation 1.82 (1.60 – 2.03) 2.03 (1.81 – 2.25) 0.066
Diabetes Concern 2.31 (2.14 – 2.48) 2.45 (2.26 – 2.64) 0.416
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exhibited better QoL perception and higher treatment 
compliance (Martínez et al., 2008).
Fear of chronic complications is common among 
DM1 patients. Independent of metabolic control and 
patient’s knowledge of the disease, a diagnosis of diabetes 
presents an uncertain picture of the future that causes 
much apprehension. The risk of micro- and macrovascular 
complications decreases when HbA1c values are 
maintained closer to 7%; however, even among patients 
with good glycemic control, there remains the fear of 
diabetes-associated conditions such as kidney damage; 
blindness; amputation; vessel disease; and heart attack, all 
of which negatively influence the diabetes concern domain 
of the DQOL-Brazil. 
Glycemic values within the therapeutic targets are 
achieved by patients who are compliant to the treatment 
and work in tandem with a health care team. Treatment 
targets must be individualized according to patient age, 
the presence of comorbidities, life expectancy, and the 
patient’s perception of his health problems. As part of 
a health care team, pharmacists, with a more extensive 
patient contact, can contribute to patient follow-up by 
providing diabetes education and self-care incentives. 
Studies have shown significant improvements in HbA1c 
values, fasting glucose levels, and compliance indicators, 
when pharmacists are included in the health care team, 
thereby improving the subjective perception of QoL 
(Correr, Otuki, 2013; Jennings, Marx, 2012; Collins et al., 
2011; Armor et al., 2010; Campbell, 2002). 
Among the participants included in this study, 
26.4% had HbA1c values ≤7.0% and 29.1% had values 
between 7.1 and 8.0%. These results differ from the 
general Brazilian population where only 10.4% of the 
DM1 patients exhibit good glycemic control (SBD, 
2011). This suggests that pharmacist intervention via 
continuous medication review with follow-up and non-
pharmacological measures can improve compliance to 
antidiabetic treatment but other methods besides HbA1c 
are necessary for more reliable results. 
Despite this efficacy evidence in Brazil, few health 
units include pharmaceutical care practice as part of the 
DM1 treatment routine. Patients treated at the 3rd Health 
Regional of Ponta Grossa-PR receive this follow-up service, 
and the results suggest that pharmaceutical intervention can 
improve health outcomes and help patients in reduction and 
maintenance of their glycemic values within the therapeutic 
targets, thus enabling a better QoL.
The number of study participants was not sufficient 
to be a representative sample and constitutes a limitation 
in obtaining more consistent results. However, our results 
indicate that glycemic control is associated with QoL and 
also that the implementation of pharmaceutical follow-up 
in health care units can improve treatment compliance, 
reduce HbA1c values, and consequently enhance diabetic 
QoL. 
We could not identify a sufficient number of 
DM1 patients treated with NPH (Neutral Protamine de 
Hagedorn) and regular insulins, or with insulin analogs 
without continuous pharmacist interventions in the city 
of Ponta Grossa. As these patients would have served as 
controls in our study, we could not perform a case-control 
comparison, which constitutes another study limitation.
Furthermore, a detailed investigation exploring 
the treatment compliance barriers and glycemic control 
in DM1 patients must be undertaken. Moreover, future 
studies are necessary to evaluate the real impact of 
pharmaceutical interventions on patient’s QoL through 
the triangulation of such methods as questionnaires, 
interviews, and focus groups, capable of obtaining 
more reliable results on the relation between treatment 
compliance and QoL. This study may be replicated in other 
cities of Brazil to update the epidemiological data on DM1.
CONCLUSIONS
DM1 patients tend to have a lower QoL due to the 
intensive health care routine they need to follow rigorously. 
This study analyzed the QoL of DM1 patients being treated 
with insulin analogs and receiving medication review with 
follow-up, analyzed the individual domain scores with 
age, gender, and glycemic control. Women demonstrated 
poorer QoL perceptions in all domains of the DQOL-
Brasil than men, and younger patients demonstrated higher 
scores, and hence higher concerns and poor QoL, in the 
social/vocational preoccupations domain. Patients with 
HbA1c ≤ 8% showed better QoL perception suggesting 
that glycemic control can impact on QoL. Helping patients 
to achieve glycemic targets is central to reducing the risk 
of complications and improving the QoL perceptions in 
DM1 patients. The inclusion of trained pharmacists in 
the health care team can be a strategy to improve diabetes 
treatment outcomes and reduce hospitalization rates in 
DM1 patients. 
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